← Lic Mutual Fund

LIC MF Healthcare Fund-Direct Plan-Growth

Equity Data as of Jun 2026 Comparing May 2026 → Jun 2026
Share: WhatsApp X
Stocks Held
23
Jun 2026
Equity Holdings
₹88.10 Cr
Equity only, excl. debt & cash
Top 5 Weight
36.8%
Moderate
Top 10 Weight
61.0%
High concentration
Changes
23
0 new · 0 exits
Top Sector
Pharmaceuticals & Biotechnology
62.5% of portfolio
📋 What Happened This Month Among existing holdings, Zydus Lifesciences Limited saw the biggest increase — now at 5.11% of the portfolio. Onesource Specialty Pharma Limited was trimmed the most, now at 2.67%. Sun Pharmaceutical Industries Limited remains the top holding with Pharmaceuticals & Biotechnology the dominant sector at 62.5%. ↓ Scroll down for full holdings, sector allocation and month-on-month changes in detail.
Sector Shift Industry allocation month-over-month
Apr 2026 May 2026
Sector Prev Curr Delta
Pharmaceuticals & Biotechnology 68.8% 60.6% -8.2%
Healthcare Services 22.6% 27.0% +4.3%
Chemicals & Petrochemicals 4.7% 5.4% +0.7%
May 2026 Jun 2026
Sector Prev Curr Delta
Pharmaceuticals & Biotechnology 60.6% 62.5% +2.0%
Healthcare Services 27.0% 27.1% +0.2%
Chemicals & Petrochemicals 5.4% 5.6% +0.2%
Biggest Add
Zydus Lifesciences Limited
+1.96% · now 5.11%
Biggest Trim
Onesource Specialty Pharma Limited
-0.41% · now 2.67%

What Changed in the Portfolio This Month?

Comparing May 2026 → Jun 2026

May 2026 Jun 2026
↑ 13 Increased ↓ 10 Decreased
#StockSectorMay 2026Jun 2026Change
1
Zydus Lifesciences Limited
₹4.73 Cr
Pharmaceuticals & Biotechnology 3.15% 5.11% +1.96%
2
Aurobindo Pharma Limited
₹4.90 Cr
Pharmaceuticals & Biotechnology 4.98% 5.30% +0.32%
3
Neuland Laboratories Limited
₹5.31 Cr
Pharmaceuticals & Biotechnology 5.49% 5.74% +0.25%
4
Gland Pharma Limited
₹3.50 Cr
Pharmaceuticals & Biotechnology 3.55% 3.79% +0.24%
5
Max Healthcare Institute Limited
₹1.89 Cr
Healthcare Services 1.82% 2.05% +0.23%
6
Navin Fluorine International Limited
₹5.16 Cr
Chemicals & Petrochemicals 5.38% 5.58% +0.20%
7
IPCA Laboratories Limited
₹2.82 Cr
Pharmaceuticals & Biotechnology 2.85% 3.05% +0.20%
8
Global Health Limited
₹2.92 Cr
Healthcare Services 2.97% 3.16% +0.19%
9
Acutaas Chemicals Ltd
₹2.22 Cr
Pharmaceuticals & Biotechnology 2.22% 2.40% +0.18%
10
Apollo Hospitals Enterprise Limited
₹6.27 Cr
Healthcare Services 6.63% 6.77% +0.14%
#StockSectorMay 2026Jun 2026Change
1
Onesource Specialty Pharma Limited
₹2.47 Cr
Pharmaceuticals & Biotechnology 3.08% 2.67% -0.41%
2
Divi's Laboratories Limited
₹6.63 Cr
Pharmaceuticals & Biotechnology 7.56% 7.17% -0.39%
3
Glenmark Pharmaceuticals Limited
₹2.64 Cr
Pharmaceuticals & Biotechnology 3.07% 2.86% -0.21%
4
Biocon Limited
₹2.66 Cr
Pharmaceuticals & Biotechnology 3.06% 2.87% -0.19%
5
Metropolis Healthcare Limited
₹2.56 Cr
Healthcare Services 2.95% 2.76% -0.19%
6
Artemis Medicare Services Limited
₹2.48 Cr
Healthcare Services 2.87% 2.68% -0.19%
7
Dr Agarwals Health Care Limited
₹1.90 Cr
Healthcare Services 2.15% 2.05% -0.10%
8
Sun Pharmaceutical Industries Limited
₹9.77 Cr
Pharmaceuticals & Biotechnology 10.61% 10.55% -0.06%
9
Anthem Biosciences Limited
₹1.95 Cr
Pharmaceuticals & Biotechnology 2.16% 2.11% -0.05%
10
Fortis Healthcare Limited
₹4.12 Cr
Healthcare Services 4.49% 4.45% -0.04%

What Stocks Does This Fund Hold?

23 stocks — Jun 2026

# Stock Sector Cap Weight & Value
1
₹9.77 Cr
Pharmaceuticals & Biotechnology
10.55%
2
₹6.63 Cr
Pharmaceuticals & Biotechnology
7.17%
3
₹6.27 Cr
Healthcare Services
6.77%
4
₹6.07 Cr
Pharmaceuticals & Biotechnology
6.55%
5
₹5.31 Cr
Pharmaceuticals & Biotechnology
5.74%
6
₹5.16 Cr
Chemicals & Petrochemicals
5.58%
7
₹4.90 Cr
Pharmaceuticals & Biotechnology
5.30%
8
₹4.73 Cr
Pharmaceuticals & Biotechnology
5.11%
9
₹4.12 Cr
Healthcare Services
4.45%
10
₹3.50 Cr
Pharmaceuticals & Biotechnology
3.79%
🏆 Top stocks held by Equity funds
See which stocks all active Equity fund managers are buying — ranked by total value invested
🏦 Lic Mutual Fund — Portfolio & Holdings
See all funds managed by Lic Mutual Fund — conviction stocks, monthly entries & exits

Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.

Found a discrepancy or have feedback? Contact Us — we read every message personally.